Intraoperative magnesium administration does not improve neurocognitive function after cardiac surgery

Stroke. 2013 Dec;44(12):3407-13. doi: 10.1161/STROKEAHA.113.002703. Epub 2013 Oct 8.

Abstract

Background and purpose: Neurocognitive decline occurs frequently after cardiac surgery and persists in a significant number of patients. Magnesium is thought to provide neuroprotection by preservation of cellular energy metabolism, blockade of the N-methyl-D-aspartate receptor, diminution of the inflammatory response, and inhibition of platelet activation. We therefore hypothesized that intraoperative magnesium administration would decrease postoperative cognitive impairment.

Methods: After approval by the Duke University Health System Institutional Review Board, 389 patients undergoing cardiac surgery were enrolled in this prospective, randomized, double-blind, placebo-controlled clinical trial. Subjects were randomized to receive magnesium as a 50 mg/kg bolus followed by another 50 mg/kg infusion for 3 hours or placebo bolus and infusion. Cognitive function was assessed preoperatively and again at 6 weeks postoperatively using a standardized test battery. Mean CD11b fluorescence and percentage of platelets expressing CD62P, which are markers of leukocyte and platelet activation, respectively, were assessed by flow cytometry as a secondary outcome. The effect of magnesium on postoperative cognition was tested using multivariable regression modeling, adjusting for age, years of education, baseline cognition, sex, race, and weight.

Results: Among the 389 allocated subjects (magnesium: n=198; placebo: n=191), the incidence of cognitive deficit in the magnesium group was 44.4% compared with 44.9% in the placebo group (P=0.93). The cognitive change score and platelet and leukocyte activation were also not different between the groups. Multivariable analysis revealed a marginal interaction between treatment group and weight such that heavier subjects receiving magnesium were less likely to have cognitive deficit (P=0.06).

Conclusions: Magnesium administered intravenously during cardiac surgery does not reduce postoperative cognitive dysfunction.

Clinical trial registration url: http://www.clinicaltrials.gov. Unique identifier: NCT00041392.

Keywords: blood platelets; cardiopulmonary bypass; cognition.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • Cardiac Surgical Procedures / adverse effects*
  • Cognition / drug effects*
  • Cognition Disorders / drug therapy
  • Cognition Disorders / etiology
  • Cognition Disorders / prevention & control*
  • Double-Blind Method
  • Female
  • Humans
  • Intraoperative Care / methods*
  • Magnesium / pharmacology
  • Magnesium / therapeutic use*
  • Male
  • Middle Aged
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use*
  • Postoperative Period
  • Treatment Outcome

Substances

  • Neuroprotective Agents
  • Magnesium

Associated data

  • ClinicalTrials.gov/NCT00041392